Considered by many observers to be the leader in the search for a coronavirus vaccine, Modern (NASDAQ: MRNA) Apparently he has decided on a price for his highly successful potential product. Quoting “people familiar with conversations between the company and potential buyers,” the Financial times He reported Tuesday that the company aims to sell its vaccine at approximately $ 50 to $ 60 per two-dose course of treatment.
That price applies to relatively prosperous countries like the United States. The article quotes “other people familiar with the plans” and says that the young biotech company has prioritized these markets. Sources in the report claim that Moderna’s prices “cause considerable concern and difficulty in negotiations, in view of the fact that other companies have promised much lower prices.”
Image source: Getty Images.
Citing the work of analyst Geoffrey Porges at SVB Leerink, the Financial times wrote that pharmaceutical multinational AstraZeneca (NYSE: AZN) It has arranged to charge certain European governments only $ 3 to $ 4 per dose for their coronavirus vaccine if, and when, it is approved and available.
There is currently no market for vaccines to prevent coronavirus and / or COVID-19, the disease it causes, as vaccine candidates have not yet been approved for such use. Moderna’s mRNA-1273, despite its relatively advanced development, barely entered phase 3 clinical trials on Monday.
The companies leading the coronavirus and COVID-19 “vaccine race” are divided over whether or not to make a profit from their work. Johnson and Johnson and AstraZeneca have said that they will not, at least in the initial stages of vaccination, while Moderna, Pfizer and Merck plans to do so.
Moderna has not commented on its apparent price adjustment. In mid-afternoon on Wednesday, in contrast to the slight rise in the main equity indices, its shares fell 2.1%.
